

GenCore version 5.1.6  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OW nucleic - nucleic search, using sw model

Run on: August 23, 2003, 14:21:52 ; Search time 343 Seconds

(without alignments)  
12222.237 Million cell updates/sec

Title: US-09-745-506-74

Perfect score: 1553

Sequence: 1 GTGATTGTTATCTGTGCT.....TCGTTTACTTAACATTCAA 1553

Scoring table: OLIGO.NUC  
Gapop 60.0 , Gapext 60.0

Searched: 2552756 seqs, 1349719017 residues

Word size : 0

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : N.Geneseq\_19Jun03.\*  
1: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:\*  
2: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:\*  
3: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:\*  
4: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:\*  
5: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:\*  
6: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:\*  
7: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:\*  
8: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:\*  
9: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:\*  
10: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:\*  
11: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:\*  
12: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:\*  
13: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:\*  
14: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:\*  
15: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:\*  
16: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:\*  
17: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:\*  
18: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:\*  
19: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:\*  
20: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:\*  
21: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2001.DAT:\*  
22: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:\*  
23: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2003.DAT:\*  
24: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2004.DAT:\*  
25: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2005.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Query	Score	Match Length	ID	Description
1	1324	85.3	1574	22	AAH16397
2	1324	85.3	1739	23	ABV23243
3	1324	85.3	1739	23	ABV29087
4	1138	73.3	1696	22	AAK60866
5	1087	70.0	1554	22	AA544644
6	1053	67.8	1053	22	AAH52212
7	846	54.5	1398	22	AAH59945
8	664	42.8	1385	24	AB160919

9	567	36.5	796	22	AAH07192	Human cDNA clone (
10	424	27.3	462	22	AAI23953	Human breast cancer
11	414	26.7	14969	22	AAK78763	Human immune/haema
12	341	22.0	1686	23	AAH85172	DNA encoding novel
13	329	21.2	514	22	AAI15105	Human breast cancer
14	223	14.4	463	22	AAK63571	Human immune/haema
15	220	14.2	465	22	ABA46423	Human breast cell
16	220	14.2	465	22	ABA57019	Human foetal liver
17	220	14.2	465	22	AAK05073	Human brain expres
18	220	14.2	465	22	AAI15235	Probe #5168 for ge
19	220	14.2	465	22	AAI04973	Probe #4964 used t
20	220	14.2	465	22	ABH30297	Human liver single
21	210	13.5	249	21	AAI25260	Human secreted pro
22	208	13.4	208	22	ABA51554	Human breast cell
23	208	13.4	208	22	ABA69581	Human foetal liver
24	208	13.4	208	22	AAK17792	Human brain expres
25	208	13.4	208	22	AAI24414	Probe #14347 for g
26	208	13.4	208	22	AAI09950	Probe #9941 used t
27	208	13.4	208	22	ABH43283	Human liver single
28	201	12.9	495	23	AAH85169	DNA encoding novel
29	188	12.1	591	23	ABV42397	Human prostate exp
30	188	12.1	720	23	ABV22093	Human prostate exp
31	188	12.1	720	23	ABV22093	Human prostate exp
32	188	12.1	720	23	ABV27892	Human prostate exp
33	188	12.1	720	23	ABV27933	Human prostate exp
34	188	12.1	720	23	ABV28038	Human prostate exp
35	154	9.9	370	23	AAH85170	DNA encoding novel
36	145	9.3	633	22	AAH34287	Human cDNA encodin
37	132	8.5	513	22	AAH44816	Human conlig polyn
38	109	7.0	273	23	ABV45380	Human prostate exp
39	109	7.0	273	23	ABV44212	Human prostate exp
40	109	7.0	443	23	ABV14293	Human prostate exp
41	105	6.8	357	23	ABV05124	Human prostate exp
42	90	5.8	339	21	AAH17249	Human secreted pro
43	72	4.6	522	23	AAH85171	DNA encoding novel
44	67	4.3	499	22	AAI23423	Human breast cancer
45	60	3.9	60	24	ABN33267	Human spliced tran

#### ALIGNMENTS

RESULT 1	AAH16397	standard; cDNA; 1574 BP.
XX	AAH16397:	
XX	26-JUN-2001	(first entry)
XX	Human cDNA sequence SEQ ID NO:15359.	
XX	Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.	
XX	Homo sapiens.	
XX	PE1074617-A2.	
XX	07-FEB-2001.	
XX	28-JUL-2000; 2000EP-0116126.	
XX	29-JUL-1999; 99JP-0248036.	
XX	27-AUG-1999; 99JP-0300253.	
XX	11-JAN-2000; 2000JP-0118776.	
XX	02-MAY-2000; 2000JP-0183767.	
XX	09-JUN-2000; 2000JP-0241899.	
XX	(HELI-) HELIX RES INST.	
XX	Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;	
XX	Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;	



PN WO200160860-A2.  
XX 23-AUG-2001.  
XX  
PF 20-FEB-2001; 2001MO-US05171.  
XX  
XX 17-FEB-2000; 2000US-183319P.  
PR 16-MAR-2000; 2000US-189862P.  
PR 25-MAY-2000; 2000US-207454P.  
PR 09-JUN-2000; 2000US-211314P.  
PR 18-JUL-2000; 2000US-219007P.  
PR 13-DEC-2000; 2000US-255281P.  
XX  
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.  
PI Schlegel R, Endege WO, Monahan JE;  
XX WPI; 2001-662795//6.  
XX  
XX Novel isolated nucleic acid molecule associated with cancerous state of  
PT prostate cells and correlating with presence of prostate cancer, useful  
PT for detecting presence of prostate cancer, stage of prostate cancer  
XX  
XX Claim 1; Page 4189-4190; 11750bp; English.  
XX  
XX The invention relates to an isolated nucleic acid molecule (I) comprising  
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the  
CC specification or its complement. (I) is useful for:  
CC (a) assessing whether a patient is afflicted with prostate cancer;  
CC (b) monitoring the progression of prostate cancer in a patient;  
CC (c) assessing the efficacy of a test compound to inhibit prostate  
CC cancer in a patient;  
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer  
CC in a patient;  
CC (e) selecting a composition for inhibiting prostate cancer in a patient;  
CC (f) assessing the prostate cell carcinogenic potential of a compound;  
CC (g) determining whether prostate cancer has metastasized in a patient;  
CC (h) assessing the aggressiveness or indolence of prostate cancer in a  
CC patient;  
CC (I) is also useful as a pharmacodynamic or pharmacogenomic marker.  
XX  
XX Sequence 1739 BP; 457 A; 389 C; 411 G; 473 T; 9 other;  
SQ  
Query Match 85.3%; Score 1324; DB 23; Length 1739;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1324; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 GTGATTGTTATCTGGTCTGTCAGAGACAGCAGAAAGAGAGATTGGGTGAGAAAACCTGC 60  
DB 53 GTGATTGTTATCTGGTCTGTCAGAGACAGCAGAAAGAGAGATTGGGTGAGAAAACCTGC 112  
QY 61 CCGGCGCAACAGACAGAGCGACAGTGGGAGAGGCGTCCGACTCAACACTTAACCTGG 120  
DB 113 CCGGCGCAACAGACAGAGCGACAGTGGGAGAGGCGTCCGACTCAACACTTAACCTGG 172  
QY 121 CTGTGTCTGTGGTCTTCTGCTGCTGAAAGAGCGCTGAAGTGGCACTGAATGAGCA 180  
DB 173 CTGTGTCTGTGGTCTTCTGCTGCTGAAAGAGCGCTGAAGTGGCACTGAATGAGCA 232  
QY 181 TAGATGATGCCACAGACAGTCCGGTTGTAGATTCCCTGATCTGCAATTCTTCCCGTTC 240  
DB 233 TAGATGATGCCACAGACAGTCCGGTTGTAGATTCCCTGATCTGCAATTCTTCCCGTTC 292  
QY 241 CTTTCATGATTTGAAGGCTCTCTCTTCTTCTGATGATGATTTGATCCCTGCTTTC 300  
DB 293 CTTTCATGATTTGAAGGCTCTCTCTTCTTCTGATGATGATTTGATCCCTGCTTTC 352  
QY 301 TGAGAGTTGGAGCAATGTTGATTACTGTGTAACCAAGCCACACATCTGTAATAC 360  
DB 353 TGAGAGTTGGAGCAATGTTGATTACTGTGTAACCAAGCCACACATCTGTAATAC 412  
QY 361 ACTCTTCTGACCAATGACCTGACTGAGGAAGTGTGAGAGAGTCTGCAAAAGAGGC 420  
|||||

DB 413 ACTCTTCTGACCAATGACCTGACTGAGAGTGTGAGAGAGTCTGCAAAAGAGGC 472  
QY 421 AGACCTATCTCTCCCAACATCCGCTATCTTCCGACCATGAAAGGCAATACCTTGAA 480  
DB 473 AGACCTATCTCTCTCCCAACATCCGCTATCTTCCGACCATGAAAGGCAATACCTTGAA 532  
QY 481 CACATGGAAGAGGCGCTGGTGTATCCGGGCTCTGAGAAAGATGCTGTACTCTCC 540  
DB 533 CACATGGAAGAGGCGCTGGTGTATCCGGGCTCTGAGAAAGATGCTGTACTCTCC 592  
QY 541 TCATACAGCTTATGATGCTCGGCCCAAGGCGTCAACACTGTTGGCTAAAGGCTTGG 600  
DB 593 TCATACAGCTTATGATGCTCGGCCCAAGGCGTCAACACTGTTGGCTAAAGGCTTGG 652  
QY 601 AGCTTGACTCTCAAGGCGCTATCTCTTCCAAAGCTCCCACTACCTTACAGAGGAAA 660  
DB 653 AGCTTGACTCTCAAGGCGCTATCTCTTCCAAAGCTCCCACTACCTTACAGAGGAAA 712  
QY 661 CCACGAGTGAATTCACGTTAACTACACCAAGACCTGAGACAAAGTCAATGCTGCAGT 720  
DB 713 CCACGAGTGAATTCACGTTAACTACACCAAGACCTGAGACAAAGTCAATGCTGCAGT 772  
QY 721 GAAAGAAATTGACGGTGTCTCTGCTCACTCTTTTCTGCTAGAGACTGTATGAGACA 780  
DB 773 GAAAGAAATTGACGGTGTCTCTGCTCACTCTTTTCTGCTAGAGACTGTATGAGACA 832  
QY 781 AACACGATTAATCTGATTAATGCTCAAGAGCTTTGATGAGGTGTATGATTTCTTTC 840  
DB 833 AACACGATTAATCTGATTAATGCTCAAGAGCTTTGATGAGGTGTATGATTTCTTTC 892  
QY 841 CCGGAACAAACACTTATATGAGAGAGGAAATCTGCTCACTGAGAGGCTTTCCTTCT 900  
DB 893 CCGGAACAAACACTTATATGAGAGAGGAAATCTGCTCACTGAGAGGCTTTCCTTCT 952  
QY 901 ACATACTGATGAGAGGAGTATGACACTGATGATCTGTCTCCCTGCAACATGAT 960  
DB 953 ACATACTGATGAGAGGAGTATGACACTGATGATCTGTCTCCCTGCAACATGAT 1012  
QY 961 TGATCGAATTAAGAAAGACACTTAATCTCATATTCGCTTACCTTGGGGTGGGAG 1020  
DB 1013 TGATCGAATTAAGAAAGACACTTAATCTCATATTCGCTTACCTTGGGGTGGGAG 1072  
QY 1021 AACCTTGAAGTCTCAAGTCAAAAGTGTGGCCCTGTGTCTGTTCTGGAGACAGCTTCT 1080  
DB 1073 AACCTTGAAGTCTCAAGTCAAAAGTGTGGCCCTGTGTCTGTTCTGGAGACAGCTTCT 1132  
QY 1081 GCAGGCTGTGAGGCTGACCTTTACCTACACAGGTGAGATGCTCCATCATATCTTGA 1140  
DB 1133 GCAGGCTGTGAGGCTGACCTTTACCTACACAGGTGAGATGCTCCATCATATCTTGA 1192  
QY 1141 TGGTGTCTCCCAAGGAATTAATGATCATCTCTGTGAACACAGCAACCTGAAGGCTT 1200  
DB 1193 TGGTGTCTCCCAAGGAATTAATGATCATCTCTGTGAACACAGCAACCTGAAGGCTT 1252  
QY 1201 TCTTTTGAAGCTTCAAGATATGCTGATTTCTCACTTGGAGAAATTAATATTAATCT 1260  
DB 1253 TCTTTTGAAGCTTCAAGATATGCTGATTTCTCACTTGGAGAAATTAATATTAATCT 1312  
QY 1261 ATCAGAGACTGACAGAGGAGCCCTTTCAGTGTGTATTAATTCAGAAACATCAGATTAAC 1320  
DB 1313 ATCAGAGACTGACAGAGGAGCCCTTTCAGTGTGTATTAATTCAGAAACATCAGATTAAC 1372  
QY 1321 ATTC 1324  
DB 1373 ATTC 1376  
RESULT 3  
ABV29087  
ID ABV29087 standard; cDNA; 1739 BP.  
XX  
XX ABV29087;  
XX

XX	16-SEP-2002	(first entry)	
XX			
DE	Human prostate expression marker	cdNA 29078.	
XX			
KW	Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;		
KW	pharmacogenomic marker; gene; sg.		
XX			
OS	Homo sapiens.		
XX			
PN	WO200160860-A2.		
XX			
PD	23-AUG-2001.		
XX			
PF	20-FEB-2001; 2001WO-US05171.		
XX			
PR	17-FEB-2000; 2000US-183319P.		
PR	16-MAR-2000; 2000US-189862P.		
PR	25-MAY-2000; 2000US-207454P.		
PR	09-JUN-2000; 2000US-211314P.		
PR	18-JUL-2000; 2000US-219007P.		
XX	13-DEC-2000; 2000US-235281P.		
XX			
PA	(MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.		
XX			
PI	Schlegel R, Endege WO, Monahan JE;		
XX			
DR	WPI; 2001-662795/76.		
XX			
PT	Novel isolated nucleic acid molecule associated with cancerous state of prostate cells and correlating with presence of prostate cancer, useful for detecting presence of prostate cancer, stage of prostate cancer -		
XX			
PS	Claim 1; Page 6170; 11750pp; English.		
XX			
CC	The invention relates to an isolated nucleic acid molecule (I) comprising a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the specification or its complement. (I) is useful for:		
CC	(a) assessing whether a patient is afflicted with prostate cancer;		
CC	(b) monitoring the progression of prostate cancer in a patient;		
CC	(c) assessing the efficacy of a test compound to inhibit prostate cancer in a patient;		
CC	(d) assessing the efficacy of a therapy for inhibiting prostate cancer in a patient;		
CC	(e) selecting a composition for inhibiting prostate cancer in a patient;		
CC	(f) assessing the prostate cell carcinogenic potential of a compound;		
CC	(g) determining whether prostate cancer has metastasized in a patient;		
CC	(h) assessing the aggressiveness or indolence of prostate cancer in a patient;		
CC	(I) is also useful as a pharmacodynamic or pharmacogenomic marker.		
CC			
CC	Sequence 1739 BP; 457 A; 389 C; 411 G; 473 T; 9 other;		
XX			
SO			
XX			
Query Match	85.3%; Score 1324; DB 23; Length 1739;		
Best Local Similarity	100.0%; Pred. No. 0;		
Matches 1324;	Conservative 0; Mismatches 0; Indels 0; Gaps 0		
QY	1 GGGATTGTTATCTTGGTGTGCTGCAGAGGACAGCAGAGAGAGATTGGGTACAGAAAATCG 60		
Db	53 GTGATTGTTATCTTGGTGTGCTGCAGAGGACAGCAGAGAGAGATTGGGTACAGAAAATCG 112		
QY	61 CCTGGCGGACACAGACACAGCGCACTAGTGGGACAGAGGGTCTGTACTAGACTTAACTGG 120		
Db	113 CCTGGCGGACACAGACACAGCGCACTAGTGGGACAGAGGGTCTGTACTAGACTTAACTGG 172		
QY	121 CTGTCGTCTGTCGTGTTTTCACATGTCCTCTGAAAAAGCGCTTAAGTCGGCAGTAATGAGGA 180		
Db	173 CTGTCGTCTGTCGTGTTTTCACATGTCCTCTGAAAAAGCGCTTAAGTCGGCAGTAATGAGGA 232		
QY	181 TAGATGATCCCCACAGACAGTCGGCTTTGTAGATTCCTCGATCTGCATTTCTCCCGTTC 240		
Db	233 TAGATGATCCCCACAGACAGTCGGCTTTGTAGATTCCTCGATCTGCATTTCTCCCGTTC 292		
QY	241 CTTCACTGATTTGAAGGCTCTCTTCTTCTTCTTGAATGACTTTGCATCCCTCGTTTGC 300		

Db	293	CTTATGATGATTGAAAGGCTCTCCCTTCTTCTTBAATGACTTTCATCCCTCTCGTTTGC	352
QY	301	TGAGAGTTGGGACAATGTTGGATTACGTGTGGGAACAAGCCACACATCTCTAAATAC	360
Db	353	TGAGAGTTGGGACAATGTTGGATTACGTGTGGGAACAAGCCACACATCTCTAAATAC	412
QY	361	ACTCTTCTTGACCAATGACCTGATGTGAGGAAGTATGAGAGAGTGGTGCAGAAAAGAGGC	420
Db	413	ACTCTTCTTGACCAATGACCTGATGTGAGGAAGTATGAGAGAGTGGTGCAGAAAAGAGGC	472
QY	421	AGACCTCATTCCTCTACCATCCGCGCTATCTTCGAGCCCATGGAAGGCGATAACCTGGAA	480
Db	473	AGACCTCATTCCTCTCTCTACCATCCGCGCTATCTTCGAGCCCATGGAAGGCGATAACCTGGAA	532
QY	481	CACATGGAAGAGGCGCTGTGTGATCCGGGCTCTGGAGAACAGAGTCGGTATCTACTCTCC	540
Db	533	CACATGGAAGAGGCGCTGTGTGATCCGGGCTCTGGAGAACAGAGTCGGTATCTACTCTCC	592
QY	541	TCATACAGACCTATATGTGTGCGCCCGCCAGAGGGGTACAACAATCGTGTGGCTAAAGGGCTTGG	600
Db	593	TCAATACAGACCTATATGTGTGCGCCCGCCAGAGGGGTACAACAATCGTGTGGCTAAAGGGCTTGG	652
QY	601	AGCTTTGATCCCTCAGGCGCCATACATACCTCTCCAAAGCTCCCAACTACCTCAGAGGGAAA	660
Db	653	AGCTTTGATCCCTCAGGCGCCATACATACCTCTCCAAAGCTCCCAACTACCTCAGAGGGAAA	712
QY	661	CCACCGAGTAGAATTCACAGTTAACTACACCCAAAGACCTGGACAAAGTCATGTCTGAGT	720
Db	713	CCACCGAGTAGAATTCACAGTTAACTACACCCAAAGACCTGGACAAAGTCATGTCTGAGT	772
QY	721	GAAAGGAATTCACGCGTGTCTGTGCACCTCTTTTCTGTGCTAGAGCTGGTATATGAGGAACA	780
Db	773	GAAAGGAATTCACGCGTGTGTGTGCACCTCTTTTCTGTGCTAGAGCTGGTATATGAGGAACA	832
QY	781	AACACGGAATTCATGAAATTTGACTTCAGAAAGCCTTATGACAGATGGTAGATTTCTTCTTC	840
Db	833	AACACGGAATTCATGAAATTTGACTTCAGAAAGCCTTATGACAGATGGTAGATTTCTTCTTC	892
QY	841	CCGGAAACAACAACCTTATATCAGAAAGACGGAATTTCTGTCACTGGAGAAAGCCTTGTCTCT	900
Db	893	CCGGAAACAACAACCTTATATCAGAAAGACGGAATTTCTGTCACTGGAGAAAGCCTTGTCTCT	952
QY	901	ACATATCTGGAATGGGACGCTTATGACACCTGGAATGATCTGTCTCTCCCTGGCAACCATGAT	960
Db	953	ACATATCTGGAATGGGACGCTTATGACACCTGGAATGATGCTGTCTCTCCCTGGCAACCATGAT	1012
QY	961	TGATCGAATTAAGAAAGACACCTTAACCTATTCATATTCGCTTACCCCTGGGGGTGGGAG	1020
Db	1013	TGATCGAATTAAGAAAGACACCTTAACCTATTCATATTCGCTTACCCCTGGGGGTGGGAG	1072
QY	1021	AACCTTAGAGCTCAAGTCAAAAGTCGTGGGCGCTGTGCTGCTGTCTGTGGAGACACGTTCT	1080
Db	1073	AACCTTAGAGCTCAAGTCAAAAGTCGTGGGCGCTGTGCTGCTGTCTGTGGAGACACGTTCT	1132
QY	1081	GCAGGGTGTGAGGCTGACCTTTACCTTCACAGGTGAGATGTCCTCATCATGATACTTTGGA	1140
Db	1133	GCAGGGTGTGAGGCTGACCTTTACCTTCACAGGTGAGATGTCCTCATCATGATACTTTGGA	1192
QY	1141	TGCGTCTCCCAAGGAATAATGTGCATCCTGTGGAACACAGCAACCTGAGCAAGGCTT	1200
Db	1193	TGCGTCTCCCAAGGAATAATGTGCATCCTGTGGAACACAGCAACCTGAGCAAGGCTT	1252
QY	1201	TCTTTCTGACCTTGAGATATGCTGAGATTCACATTTGGAGAAATAGATTAATATATATCT	1260
Db	1253	TCTTTCTGACCTTGAGATATGCTGAGATTCACATTTGGAGAAATAGATTAATATATATCT	1312
QY	1261	ATCAGAGACTGACAGGGAACCTCTTCAGAGTGTATTAATTGCAGAAATCATCGATGATTAAC	1320
Db	1313	ATCAGAGACTGACAGGGAACCTCTTCAGAGTGTATTAATTGCAGAAATCATCGATGATTAAC	1372
QY	1321	ATTC 1324	

Db 1373 ATTC 1376

RESULT 4  
ID AAK60866 standard; cDNA; 1696 BP.  
XX  
XX AAK60866;  
XX  
DT 06-NOV-2001 (first entry)  
XX  
DE Human immune/haematopoietic antigen encoding cDNA SEQ ID NO:5926.  
XX  
XX Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;  
KW cytostatic; gene therapy; vaccine; metastasis; ss.  
XX  
OS Homo sapiens.  
XX  
PN W0200157182-A2.  
XX  
PD 09-AUG-2001.  
XX  
PF 17-JAN-2001; 2001WO-US01354.  
XX  
XX 31-JAN-2000; 2000US-0179065.  
PR 04-FEB-2000; 2000US-0180628.  
PR 24-FEB-2000; 2000US-0184664.  
PR 02-MAR-2000; 2000US-0186350.  
PR 16-MAR-2000; 2000US-0189874.  
PR 17-MAR-2000; 2000US-0190076.  
PR 18-APR-2000; 2000US-0198123.  
PR 19-MAY-2000; 2000US-0205515.  
PR 07-JUN-2000; 2000US-0209467.  
PR 28-JUN-2000; 2000US-0214886.  
PR 30-JUN-2000; 2000US-0215135.  
PR 07-JUL-2000; 2000US-0216647.  
PR 07-JUL-2000; 2000US-0216880.  
PR 11-JUL-2000; 2000US-0217487.  
PR 11-JUL-2000; 2000US-0217496.  
PR 14-JUL-2000; 2000US-0218290.  
PR 26-JUL-2000; 2000US-0220963.  
PR 26-JUL-2000; 2000US-0220964.  
PR 14-AUG-2000; 2000US-0224518.  
PR 14-AUG-2000; 2000US-0224519.  
PR 14-AUG-2000; 2000US-0225213.  
PR 14-AUG-2000; 2000US-0225214.  
PR 14-AUG-2000; 2000US-0225266.  
PR 14-AUG-2000; 2000US-0225267.  
PR 14-AUG-2000; 2000US-0225268.  
PR 14-AUG-2000; 2000US-0225270.  
PR 14-AUG-2000; 2000US-0225447.  
PR 14-AUG-2000; 2000US-0225757.  
PR 14-AUG-2000; 2000US-0225758.  
PR 14-AUG-2000; 2000US-0225759.  
PR 18-AUG-2000; 2000US-0226279.  
PR 22-AUG-2000; 2000US-0226681.  
PR 22-AUG-2000; 2000US-0226688.  
PR 22-AUG-2000; 2000US-0227182.  
PR 30-AUG-2000; 2000US-0227009.  
PR 30-AUG-2000; 2000US-0228924.  
PR 01-SEP-2000; 2000US-0229287.  
PR 01-SEP-2000; 2000US-0229343.  
PR 01-SEP-2000; 2000US-0229344.  
PR 01-SEP-2000; 2000US-0229345.  
PR 05-SEP-2000; 2000US-0229509.  
PR 05-SEP-2000; 2000US-0229513.  
PR 06-SEP-2000; 2000US-0230437.  
PR 06-SEP-2000; 2000US-0230438.  
PR 08-SEP-2000; 2000US-0231242.  
PR 08-SEP-2000; 2000US-0231243.  
PR 08-SEP-2000; 2000US-0231244.  
PR 08-SEP-2000; 2000US-0231413.  
PR 08-SEP-2000; 2000US-0231414.  
PR 08-SEP-2000; 2000US-0232080.  
PR 08-SEP-2000; 2000US-0232081.  
PR 12-SEP-2000; 2000US-0231968.  
PR 14-SEP-2000; 2000US-0232387.  
PR 14-SEP-2000; 2000US-0232398.  
PR 14-SEP-2000; 2000US-0232399.  
PR 14-SEP-2000; 2000US-0232400.  
PR 14-SEP-2000; 2000US-0232401.  
PR 14-SEP-2000; 2000US-0233063.  
PR 14-SEP-2000; 2000US-0233064.  
PR 14-SEP-2000; 2000US-0233065.  
PR 21-SEP-2000; 2000US-0234223.  
PR 21-SEP-2000; 2000US-0234274.  
PR 25-SEP-2000; 2000US-0234997.  
PR 25-SEP-2000; 2000US-0234998.  
PR 26-SEP-2000; 2000US-0235484.  
PR 27-SEP-2000; 2000US-0235834.  
PR 27-SEP-2000; 2000US-0235836.  
PR 29-SEP-2000; 2000US-0236327.  
PR 29-SEP-2000; 2000US-0236367.  
PR 29-SEP-2000; 2000US-0236368.  
PR 29-SEP-2000; 2000US-0236369.  
PR 29-SEP-2000; 2000US-0236370.  
PR 02-OCT-2000; 2000US-0236802.  
PR 02-OCT-2000; 2000US-0237037.  
PR 02-OCT-2000; 2000US-0237038.  
PR 02-OCT-2000; 2000US-0237039.  
PR 02-OCT-2000; 2000US-0237040.  
PR 13-OCT-2000; 2000US-0239935.  
PR 13-OCT-2000; 2000US-0239937.  
PR 20-OCT-2000; 2000US-0240960.  
PR 20-OCT-2000; 2000US-0241221.  
PR 20-OCT-2000; 2000US-0241785.  
PR 20-OCT-2000; 2000US-0241786.  
PR 20-OCT-2000; 2000US-0241787.  
PR 20-OCT-2000; 2000US-0241808.  
PR 20-OCT-2000; 2000US-0241809.  
PR 20-OCT-2000; 2000US-0241826.  
PR 01-NOV-2000; 2000US-0244617.  
PR 08-NOV-2000; 2000US-0246474.  
PR 08-NOV-2000; 2000US-0246475.  
PR 08-NOV-2000; 2000US-0246476.  
PR 08-NOV-2000; 2000US-0246477.  
PR 08-NOV-2000; 2000US-0246478.  
PR 08-NOV-2000; 2000US-0246523.  
PR 08-NOV-2000; 2000US-0246524.  
PR 08-NOV-2000; 2000US-0246525.  
PR 08-NOV-2000; 2000US-0246526.  
PR 08-NOV-2000; 2000US-0246527.  
PR 08-NOV-2000; 2000US-0246528.  
PR 08-NOV-2000; 2000US-0246532.  
PR 08-NOV-2000; 2000US-0246609.  
PR 08-NOV-2000; 2000US-0246610.  
PR 08-NOV-2000; 2000US-0246611.  
PR 08-NOV-2000; 2000US-0246613.  
PR 17-NOV-2000; 2000US-0249207.  
PR 17-NOV-2000; 2000US-0249208.  
PR 17-NOV-2000; 2000US-0249209.  
PR 17-NOV-2000; 2000US-0249210.  
PR 17-NOV-2000; 2000US-0249211.  
PR 17-NOV-2000; 2000US-0249212.  
PR 17-NOV-2000; 2000US-0249213.  
PR 17-NOV-2000; 2000US-0249214.  
PR 17-NOV-2000; 2000US-0249215.  
PR 17-NOV-2000; 2000US-0249216.  
PR 17-NOV-2000; 2000US-0249217.  
PR 17-NOV-2000; 2000US-0249218.  
PR 17-NOV-2000; 2000US-0249244.  
PR 17-NOV-2000; 2000US-0249245.  
PR 17-NOV-2000; 2000US-0249264.  
PR 17-NOV-2000; 2000US-0249265.  
PR 17-NOV-2000; 2000US-0249287.  
PR 17-NOV-2000; 2000US-0249297.  
PR 17-NOV-2000; 2000US-0249299.

PR 17-NOV-2000; 2000US-0249300.  
PR 01-DEC-2000; 2000US-0250160.  
PR 01-DEC-2000; 2000US-0250391.  
PR 05-DEC-2000; 2000US-0251030.  
PR 05-DEC-2000; 2000US-0251988.  
PR 05-DEC-2000; 2000US-0256719.  
PR 06-DEC-2000; 2000US-0251479.  
PR 08-DEC-2000; 2000US-0251856.  
PR 08-DEC-2000; 2000US-0251868.  
PR 08-DEC-2000; 2000US-0251869.  
PR 08-DEC-2000; 2000US-0251989.  
PR 08-DEC-2000; 2000US-0251990.  
PR 11-DEC-2000; 2000US-0254097.  
PR 05-JAN-2001; 2001US-0259678.  
XX  
XX  
XX  
XX (HUMA-) HUMAN GENOME SCI INC.  
XX  
XX  
XX Rosen CA, Barash SC, Ruben SM;  
XX  
XX WPI; 2001-483426/52.  
XX P-PSDB; AAM88085.  
XX  
XX Nucleic acids encoding human immune/hematopoietic antigen polypeptides,  
XX PT useful for preventing, diagnosing and/or treating cancers and  
XX metastasis -  
XX  
XX Claim 1; SEQ ID NO 5926; 3071pp + Sequence Listing; English.

CC AAK5495 to AAK64702 encode the human immune/haematopoietic antigen (I)  
CC amino acid sequences given in AAM82170 to AAM91521. (I) have cytostatic  
CC activity, and can be used in gene therapy and vaccine production. (I)  
CC treatment of polynucleotides may be used in the prevention, diagnosis and  
CC treatment of diseases associated with inappropriate (I) expression. For  
CC example, they may be used to treat disorders associated with decreased  
CC expression by rectifying mutations or deletions in a patient's genome  
CC that affect the activity of (I) by expressing inactive proteins or to  
CC supplement the patients own production of (I). Additionally, (I)  
CC polynucleotides may be used to produce the secreted (I), by inserting  
CC the nucleic acids into a host cell and culturing the cell to express the  
CC protein. (I) proteins and polynucleotides may be used to prevent,  
CC diagnose and treat immune/haematopoietic-related diseases, especially  
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703  
CC to AAK67694 represent human immune/haematopoietic antigen genomic  
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169  
CC represent sequences used in the exemplification of the present invention.  
CC  
CC  
CC Sequence 1696 BP; 510 A; 369 C; 379 G; 435 T; 3 other;  
CC  
CC

	Query Match	73.3%	Score 1138:	DB 22:	Length 1696:
	Best Local Similarity	100.0%	Pred. No. 0:		
	Matches 1138:	Conservative 0:	Mismatches 0:	Indels 0:	Gaps 0:
OY	187	AGTCCCCAGCAGACGCGGTTGTGTGATTCCTGTATCCGTATCCGCAATTTCTCCGTTCCCTCAT			246
Db	249	AGTCCCCAGCAGACGCGGTTGTGTGATTCCTGTATCCGTATCCGCAATTTCTCCGTTCCCTCAT			308
OY	247	GGATTTGAAGGCTCTCCTTTCTCCCTTAATGACTTTGCATCCCTCGTGTTCGAGAG			306
Db	309	GGATTTGAAGGCTCTCCTTTCTCCCTTAATGACTTTGCATCCCTCGTGTTCGAGAG			368
OY	307	TTGGGACATGTTGGATTACTGTGTGGAACCAAGCCACACACTGTGTAATACACTCTT			366
Db	369	TTGGGACATGTTGGATTACTGTGTGGAACCAAGCCACACACTGTGTAATACACTCTT			428
OY	367	CCTGACCAATGACCTGACTGAGGAAGTATGGAGAGGTGCTGCGAAAAAGAGGACGACTT			426
Db	429	CCTGACCAATGACCTGACTGAGGAAGTATGGAGAGGTGCTGCGAAAAAGAGGACGACTT			488
OY	427	CATTCTCCTACCAATCCGCTATTTCCGACCCCTGGAAGGCGATTAACCTGGACACATG			486
Db	489	CATTCTCCTACCAATCCGCTATTTCCGACCCCTGGAAGGCGATTAACCTGGACACATG			548
OY	487	GAAAGAGCGCTGGTGATCCGGGCTCTGGAGAACAGAGTCCGTAATCTACTCTCCATAC			546

Db	549	GAAGAGCGCCTGGTGTATCCGGGCTCTGGAGAAAGABTCCGATATCTACTCTCTCAATAC	608
QY	547	AGCCTATGATCTCGCGGCCACAGGGCGTCAACAACTGGTTGGCTAAAGGCTTGGAGCTTG	606
Db	609	AGCCTATGATCTCGCGGCCACAGGGCGTCAACAACTGGTTGGCTAAAGGCGCTTGGAGCTTG	668
QY	607	TACCTCCAGGCCCCATACATCTCTTCCAAAGCTCCCAACTACTCCCTACAGAGGAAACACACG	666
Db	669	TACCTCCAGGCCCCATACATCTCTTCCAAAGCTCCCAACTACTCCCTACAGAGGAAACACACG	728
QY	667	AGTGAATTCAAGGTTAACTACACCAAGACTGAGACAAAGTCAATGTCGTGAGTGAAGG	726
Db	729	AGTGAATTCAAGGTTAACTACACCAAGACTGAGACAAAGTCAATGTCGTGAGTGAAGG	788
QY	727	AATTGACGCGTCTTCTGTCACTCTTTTCTTGCTAGAGACTGGTATGAGAAACAACAG	786
Db	789	AATTGACGCGTCTTCTGTCACTCTTTTCTTGCTAGAGACTGGTATGAGAAACAACAG	848
QY	787	GATTAAATCTGAATTGTACTCAGAAAGCGTTTGATGACAGGTTGATATTTCTTCCGGAA	846
Db	849	GATTAAATCTGAATTGTACTCAGAAAGCGTTTGATGACAGGTTGATATTTCTTCCGGAA	908
QY	847	CAAAACACTTTATCAGAAAGACGAAATTTCTGTCACTGGAGAAAGCTTTGCTTCACTAC	906
Db	909	CAAAACACTTTATCAGAAAGACGAAATTTCTGTCACTGGAGAAAGCTTTGCTTCACTAC	968
QY	907	TGGAATGGAGCGGTTATGACACACAGATGATCTGTCTCCCTGGCAACATGATGATACG	966
Db	969	TGGAATGGAGCGGTTATGACACACAGATGATCTGTCTCCCTGGCAACATGATGATACG	1028
QY	967	AATAAAAAGACACCTAAAACTATCTCATATTTGGTTAGCCCTTGGGGTGGGAGAACCTT	1026
Db	1029	AATAAAAAGACACCTAAAACTATCTCATATTTGGTTAGCCCTTGGGGTGGGAGAACCTT	1088
QY	1027	AGAGCTCTCAAGTCAAAGTCGTGGCCCTGTGTGCTGGTTCTTGGAGACAGCCTTTCGACGG	1086
Db	1089	AGAGCTCTCAAGTCAAAGTCGTGGCCCTGTGTGCTGGTTCTTGGAGACAGCCTTTCGACGG	1148
QY	1087	TGTTGAGCGTCAACCTTTTACTCTCAAGAGGAGATGTCCCATGATATATCTTTGGATGTGC	1146
Db	1149	TGTTGAGCGTCAACCTTTTACTCTCAAGAGGAGATGTCCCATGATATATCTTTGGATGTGC	1208
QY	1147	TTCCCAAGAAATPAAATGTCTATCTCTGTGGAACACAGCAACACTGACAGGCTTCTTTC	1206
Db	1209	TTCCCAAGAAATPAAATGTCTATCTCTGTGGAACACAGCAACACTGACAGGCTTCTTTC	1268
QY	1207	TGACCTTGGAATATGCTGGAATTTCTCACTTGGAAATPAAATPAAATATATCCATACGA	1266
Db	1269	TGACCTTGGAATATGCTGGAATTTCTCACTTGGAAATPAAATPAAATATATCCATACGA	1328
QY	1267	GACTGACAGGAGACCCCTTTCAGGTGGTAAATTCAGAAACATCAGATAACATATTC	1324
Db	1329	GACTGACAGGAGACCCCTTTCAGGTGGTAAATTCAGAAACATCAGATAACATATTC	1386

KW antibacterial; immunosuppressive; vasotropic; antiparkinsonian;  
KM neuroprotective; osteopathic; antidiabetic; antiallergic;  
KW immunostimulant; analgesic; gene therapy.  
XX  
OS Homo sapiens.  
XX  
XX MO200164834-A2.  
XX  
PD 07-SEP-2001.  
XX  
XX 26-FEB-2001; 2001WO-US04926.  
XX  
XX 28-FEB-2000; 2000US-0515126.  
PR 18-MAY-2000; 2000US-0577409.  
PR 17-JUN-2000; 2000US-0597707.  
PR 14-JUL-2000; 2000US-0616807.  
PR 19-SEP-2000; 2000US-0664641.  
XX  
XX (HYSE-) HYSEQ INC.  
XX  
PI Tang YF, Liu C, Zhou P, Asundi V, Zhang J, Zhao QH, Fen F,  
PI Xue AJ, Yang Y, Wehrman T, Wang J, Ma Y, Wang D, Chen R, Xu C;  
PI Drmanac R;  
XX WPI: 2001-589862/66.  
DR P-PSDB; AAU27744.  
XX  
XX Novel polypeptides and nucleic acids obtained from cDNA libraries  
PT prepared from various human tissues, for diagnosis, treatment of  
PT cancer, neurological, inflammatory disorders and for use in arrays for  
PT detection -  
XX  
PS Claim 1; SEQ ID No 69; 153pp; English.  
XX  
CC Sequences A544576-A544919 represent full-length polynucleotides and  
CC and protein sequences encoding polypeptides of the invention. The DNA  
CC and protein sequences are useful for the treatment, diagnosis and  
CC prevention of various types of disorder in a mammalian subject such as a  
CC human, dog, monkey, mouse, hamster or rat. The disorders include cancers  
CC such as leukemia, lymphoma and neuroblastoma, autoimmune disorders such  
CC as multiple sclerosis, connective tissue disease, rheumatoid arthritis,  
CC diabetes mellitus, allergic rhinitis, asthma and eczema, nervous system  
CC disorders such as Parkinson's disease, Alzheimer's disease, Huntington's  
CC chorea, amyotrophic lateral sclerosis, spinal muscular atrophy and  
CC Menckie disease, inflammatory disorders such as nephritis, Crohn's  
CC disease, ischemia-reperfusion injury, shock, sepsis and inflammatory  
CC bowel disease. The sequences exhibit activity relating to angiogenesis,  
CC cell proliferation, cell differentiation, stem cell growth factor,  
CC activin or inhibin. Therefore, they can be used to manipulate stem cells  
CC in culture to give rise to neuroepithelial cells that can be used to  
CC augment or replace cells damaged by illness, accidental damage or genetic  
CC disorders. The sequences may also be used for regeneration of bone,  
CC cartilage, tendons and ligaments and in tissue repair and burn healing.  
CC Note: Some sequences for this patent did not form part of the printed  
CC specification, but were obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequences.  
XX  
XX Sequence 1554 BP: 428 A; 358 C; 346 G; 422 T; 0 other:  
SO

Query Match 70.0%; Score 1087; DB 22; Length 1554;  
Best Local Similarity 99.9%; Pred. No. 0;  
Matches 1137; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 187 AGTCCCAAGCAGCAGTCCGCTTGTGATGATCCCTGATGCAATTCCTCCGTTCTTCAT 246  
DB 178 AGTCCCAAGCAGCAGTCCGCTTGTGATGATCCCTGATGCAATTCCTCCGTTCTTCAT 237  
QY 247 GGATTTGAAGCTCTCCCTTCTCTGATGATGATCCCTGATGCAATTCCTCCGTTCTTCAT 306  
DB 238 GGATTTGAAGCTCTCCCTTCTCTGATGATGATCCCTGATGCAATTCCTCCGTTCTTCAT 297  
QY 307 TTGGACAATGTTGATTTACTGTTGGAACCAAGCCACACATATGTAATATACACTCTT 366  
|||||

DB 298 TTGGACAATGTTGATTTACTGTTGGAACCAAGCCACACATATGTAATATACACTCTT 357  
QY 367 CCTGACCAATGATACCTGACTGAGGAAGTATGAGAGAGTCTGCAAAAAGAGGAGACT 426  
DB 358 CCTGACCAATGATACCTGACTGAGGAAGTATGAGAGAGTCTGCAAAAAGAGGAGACT 417  
QY 427 CATTCCTGCTACCACTCCGCTATCTTCTGCAAGCCATGAAGGCAATTAACCTGAACATG 486  
DB 418 CATTCCTGCTACCACTCCGCTATCTTCTGCAAGCCATGAAGGCAATTAACCTGAACATG 477  
QY 487 GAAGAGGCGCTGTGATCCGGGCTCTGAGAAACAGATCGGTATCTACTCTCTCATAC 546  
DB 478 GAAGAGGCGCTGTGATCCGGGCTCTGAGAAACAGATCGGTATCTACTCTCTCATAC 537  
QY 547 AGCCATGATGCTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 606  
DB 538 AGCCATGATGCTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 597  
QY 607 TACCTCCAGGCCATACATCTCTCCAAAGCTCCCAACTACCTACAGAGGGAACACCG 666  
DB 598 TACCTCCAGGCCATACATCTCTCCAAAGCTCCCAACTACCTACAGAGGGAACACCG 657  
QY 667 AGTAGAATTCACAGTTAACTACACCCAAAGCTGAGACAAAGTATGTCAGTGAAGG 726  
DB 658 AGTAGAATTCACAGTTAACTACACCCAAAGCTGAGACAAAGTATGTCAGTGAAGG 717  
QY 727 AATTGACGCTGTTTCTGACCTCTTTTCTGCTAGAGTGTATGAGAAACAAACG 786  
DB 718 AATTGACGCTGTTTCTGACCTCTTTTCTGCTAGAGTGTATGAGAAACAAACG 777  
QY 787 GATTATATGTAATTTACTACAGAAAGCTTTGAGAGTGTATGAGAAACAAACG 846  
DB 778 GATTATATGTAATTTACTACAGAAAGCTTTGAGAGTGTATGAGAAACAAACG 837  
QY 847 CAACACACTTATATCAGAAAGAGGAATTTCTGACTGAGAAAGCTTTGCTTCAATAC 906  
DB 838 CAACACACTTATATCAGAAAGAGGAATTTCTGACTGAGAAAGCTTTGCTTCAATAC 897  
QY 907 TGGAAATGAGAGGTTATGACACCTGAGAAATCTGTCCTCCGGAACCATGATGATG 966  
DB 898 TGGAAATGAGAGGTTATGACACCTGAGAAATCTGTCCTCCGGAACCATGATGATG 957  
QY 967 AATAAAGAGACACTTAAATATCTATATTCATATTCCTTAAAGCTTTGGGTTGGAGAACTT 1026  
DB 958 AATAAAGAGACACTTAAATATCTATATTCATATTCCTTAAAGCTTTGGGTTGGAGAACTT 1017  
QY 1027 AGAGTCTCAAGTCAAGTCTGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1086  
DB 1018 AGAGTCTCAAGTCAAGTCTGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1077  
QY 1087 TGTGAGGCTGACCTTACCTACAGAGTGAATGCCATCATGATGATGATGATGATGATG 1146  
DB 1078 TGTGAGGCTGACCTTACCTACAGAGTGAATGCCATCATGATGATGATGATGATGATG 1137  
QY 1147 TTCCCAAGAAATTAATGTCATCTCTGTAACACAGCAACACTGAAAGAGCTTCTTTC 1206  
DB 1138 TTCCCAAGAAATTAATGTCATCTCTGTAACACAGCAACACTGAAAGAGCTTCTTTC 1197  
QY 1267 GACTACAGGAGACCTTCTTCAAGTGTATATGCAAGAACTCAGAGTACACATTC 1324  
DB 1258 GACTACAGGAGACCTTCTTCAAGTGTATATGCAAGAACTCAGAGTACACATTC 1315

RESULT 6  
AAH52212  
ID AAH52212 standard; cDNA: 1053 BP.  
XX  
XX AC AAH52212;  
XX







PI L1 N, Xiao H, Liu F;  
 XX WPI: 2001-183596/19.  
 DR P-PSDB: AAB60663.  
 XX  
 PT Human gene expression regulatory factor related protein and its coded  
 sequence -  
 XX  
 PS Claim 1: Page 18-19; 20pp: Chinese.  
 XX  
 CC The invention relates to a novel human gene expression regulatory  
 CC factor-related protein, hnrf3-s (NGF1-interacting factor, AAB60663),  
 CC and cDNA encoding it (AAFS9945). hnrf3-s is expressed in haemopoietic  
 CC stem cells. The invention also relates to the preparation of hnrf3-s  
 CC proteins and nucleic acids, and the detection of hnrf3-s proteins and  
 CC nucleic acids in a sample. The present sequence represents cDNA encoding  
 CC hnrf3-s.  
 XX  
 XX Sequence 1398 BP; 365 A; 331 C; 342 G; 360 T; 0 other;  
 SQ  
 Query Match 54.58; Score 846; DB 22; Length 1398;  
 Best Local Similarity 99.78; Pred. No. 0;  
 Matches 1196; Conservative 0; Mismatches 1; Indels 3; Gaps 2;

QY 128 TCCTGTTTTCACCTGCTGTAAGAGCCCTGAAGTGCACATGAATGAGCATATGTA 187  
 DB 119 TCGTGGTTTTCACCTGCTGTAAGAGCCCTGAAGTGCACATGAATGAGCATATGTA 178  
 QY 188 GTCCCCACGACAGTCCGGTTTGAATGATCCCTGATCTGCAATTCCTCCCTTCATG 247  
 DB 179 GTCCCCACGACAGTCCGGTTTGAATGATCCCTGATCTGCAATTCCTCCCTTCATG 238  
 QY 248 GATTGGAAGGCT 307  
 DB 239 GATTGGAAGGCT 298  
 QY 308 TGGGACAATGTTGATTAATGATGTAAGCAAGCCACACATCTGTAATATACACTCTTC 367  
 DB 299 TGGGACAATGTTGATTAATGATGTAAGCAAGCCACACATCTGTAATATACACTCTTC 358  
 QY 368 CTGACCAATGACTGACTGAGAAAGTATGAGAGAGTCTGCAAAAAGAAAGGACACTC 427  
 DB 359 CTGACCAATGACTGACTGAGAAAGTATGAGAGAGTCTGCAAAAAGAAAGGACACTC 418  
 QY 428 ATTCTCTCCACCATCCGCTATCTCTCCGACCATGAGGGA-TAACCTGGACACATG 486  
 DB 419 ATTCTCTCCACCATCCGCTATCTCTCCGACCATGAGGGA-TAACCTGGACACATG 478  
 QY 487 G--AAGGAGCGCTGATCCGGCTCTGAGAAAGAGTCCGATCTCTCTCTCAT 544  
 DB 479 GGAAGGAGCGCTGATCCGGCTCTGAGAAAGAGTCCGATCTCTCTCTCAT 538  
 QY 545 ACAAGCTATGATCTGCGCCCAAGGGCGTCAACAACCTGTTGCTAAAGGGCTTGAAGCT 604  
 DB 539 ACAAGCTATGATCTGCGCCCAAGGGCGTCAACAACCTGTTGCTAAAGGGCTTGAAGCT 598  
 QY 605 TTAGCTCCAGGCGCCATCATCTCTCCAAAGCTCCCAACATCCCTAAGAGGGAACAC 664  
 DB 599 TTAGCTCCAGGCGCCATCATCTCTCCAAAGCTCCCAACATCCCTAAGAGGGAACAC 658  
 QY 665 CGAGTAGAATTCACGTTAATCAACCAAGACCTGAGCAAAAGTATGATGAGTGA 724  
 DB 659 CGAGTAGAATTCACGTTAATCAACCAAGACCTGAGCAAAAGTATGATGAGTGA 718  
 QY 725 GGAATGAGCGGTCT 784  
 DB 719 GGAATGAGCGGTCT 778  
 QY 785 CGGATTAATCTGAATTTACTACAGAAAGCTTTGATGAGGAGGAGATTTCTCTCCCG 844  
 DB 779 CGGATTAATCTGAATTTACTACAGAAAGCTTTGATGAGGAGGAGATTTCTCTCCCG 838  
 QY 845 AACAAACACTTATATCAGAAAGGAAATTCCTGCTACTGAGAGAGCTTCTGCTTCTCAT 904

DB 839 AACAAACACTTATATCAGAAAGGAAATTCCTGCTACTGAGAGAGCTTCTGCTTCTCAT 898  
 QY 905 ACTGGAATGGGACGGTATATGACACACTGATGAAATCTGTCCCTGGCAACCATATGAT 964  
 DB 899 ACTGGAATGGGACGGTATATGACACACTGATGAAATCTGTCCCTGGCAACCATATGAT 958  
 QY 965 CGAATTAAGAGACACTTAAACATCTATCTATCTGCTTACGCCCTTGGGGTGGGAGAAC 1024  
 DB 959 CGAATTAAGAGACACTTAAACATCTATCTATCTGCTTACGCCCTTGGGGTGGGAGAAC 1018  
 QY 1025 TTAGAGTCTCAAGTCAAAAGTGTGGCCCTGTGCTGCTGTTCTGGGACAGGCTTCTCAG 1084  
 DB 1019 TTAGAGTCTCAAGTCAAAAGTGTGGCCCTGTGCTGCTGTTCTGGGACAGGCTTCTCAG 1078  
 QY 1085 GGTGTTAGAGCTGACCTTTTACTCTACAGGTGATGTCCTCATCATGATCTTGGATGCT 1144  
 DB 1079 GGTGTTAGAGCTGACCTTTTACTCTACAGGTGATGTCCTCATCATGATCTTGGATGCT 1138  
 QY 1145 GCTTCCCAAGGAATTAATGTCATCTCTGTAACACAGCAACACTGAACGAGGCTTCTT 1204  
 DB 1139 GCTTCCCAAGGAATTAATGTCATCTCTGTAACACAGCAACACTGAACGAGGCTTCTT 1198  
 QY 1205 TCTGACCTTGCAGATATGCTGATTTCTCACTTGGAGATAATTAATATCTATCA 1264  
 DB 1199 TCTGACCTTGCAGATATGCTGATTTCTCACTTGGAGATAATTAATATCTATCA 1258  
 QY 1265 GAGACTGACAGGACCTCTTCAAGGTGATTAATTCAGAAATCAACGATACACATTC 1324  
 DB 1259 GAGACTGACAGGACCTCTTCAAGGTGATTAATTCAGAAATCAACGATACACATTC 1318

RESULT 8  
 ID ABL60919  
 AB 60919 standard; cDNA: 1385 BP.  
 XX  
 AC ABL60919;  
 XX  
 DT 23-SEP-2002 (first entry)  
 XX  
 DE Human protein kinase C 27.17 polypeptide encoding cDNA.  
 XX  
 KW Human; protein kinase C 27.17; protein metabolism; gene; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT CDS 389..1132  
 FT /\*tag= a  
 FT /product= "protein kinase C 27.17 polypeptide"  
 XX  
 PN CNI333355-A.  
 XX  
 PD 30-JAN-2002.  
 XX  
 PF 07-JUL-2000; 2000CN-0117049.  
 XX  
 PR 07-JUL-2000; 2000CN-0117049.  
 XX  
 PA (SHAN-) SHANGHAI BIODOOR GENE DEV CO LTD.  
 XX  
 PI Mao Y, Xie Y;  
 XX  
 DR WPI: 2002-305609/35.  
 DR P-PSDB: ABB08182.  
 XX  
 PT Human protein kinase C 27.17 polypeptide and its encoding  
 PT polynucleotide, for treating e.g. protein metabolism disturbance -  
 PS Claim 6; Page 25-26 (disclosure); 33pp: Chinese.  
 XX  
 CC The invention relates to a human protein kinase C 27.17 polypeptide and  
 CC its encoding polynucleotide. The polypeptide can be expressed by standard

CC DNA recombination. The polynucleotide, polypeptide and its antagonist are  
 CC useful for treating e.g. protein metabolism disturbance. The present  
 CC sequence represents the human protein kinase C 27.17 polypeptide encoding  
 CC cDNA.

XX  
 SQ Sequence 1385 BP; 375 A; 324 C; 308 G; 378 T; 0 other;

Query Match 42.8%; Score 664; DB 24; Length 1385;  
 Best Local Similarity 100.0%; Pred. No. 0;  
 Matches 664; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 661 CCACGAGTAAATTCACAGTAACTACACCCCAAGACCTGGCAAGTCAATCTGCACT 720  
 DB 496 CCACGAGTAAATTCACAGTAACTACACCCCAAGACCTGGCAAGTCAATCTGCACT 555  
 QY 721 GAAAGAAATTCAGAGTCTTCTGCTACCTCTTTCTGCTAGAGTGAATGAGAGACA 780  
 DB 556 GAAAGAAATTCAGAGTCTTCTGCTACCTCTTTCTGCTAGAGTGAATGAGAGACA 615  
 QY 781 AACACGATTAATTCGAATTTGACTCAGAGGCTTTGATGACAGTGTGATATTTCTTTC 840  
 DB 616 AACACGATTAATTCGAATTTGACTCAGAGGCTTTGATGACAGTGTGATATTTCTTTC 675  
 QY 841 CCGGAACAAACACTTATCAGAGAGCGAAATTTCTGTCACAGGAGAAACCTTTGCTTCT 900  
 DB 676 CCGGAACAAACACTTATCAGAGAGCGAAATTTCTGTCACAGGAGAAACCTTTGCTTCT 735  
 QY 901 ACATACGATGAGAGGCTTATGACACACTGATGATCTGCTCCCTGGCAACATGAT 960  
 DB 736 ACATACGATGAGAGGCTTATGACACACTGATGATCTGCTCCCTGGCAACATGAT 795  
 QY 961 TGATGATTAATAAAGACACCTTAACTATCTCATATTCCTTAGCCCTTGGGGGGAG 1020  
 DB 796 TGATGATTAATAAAGACACCTTAACTATCTCATATTCCTTAGCCCTTGGGGGGAG 855  
 QY 1021 AACCTTAGCTCAAGTCAAGTGGGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1080  
 DB 856 AACCTTAGCTCAAGTCAAGTGGGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 915  
 QY 1081 GCAGGGTGTGAGGCTGACCTTACCTCAGAGTGAATGTCATCATGATGATCTTGA 1140  
 DB 916 GCAGGGTGTGAGGCTGACCTTACCTCAGAGTGAATGTCATCATGATGATCTTGA 975  
 QY 1141 TCTCTCTTCCCAAGAAATTAATGTCATCTCTGTGAACACACGACACGAGAGCTT 1200  
 DB 976 TCTCTCTTCCCAAGAAATTAATGTCATCTCTGTGAACACACGAGAGCTT 1035  
 QY 1201 TCTCTCTGACCTTCGAGATATGCTGATCTCAGCTTGGAGAAATTAATTAATCTCT 1260  
 DB 1036 TCTCTCTGACCTTCGAGATATGCTGATCTCAGCTTGGAGAAATTAATTAATCTCT 1095  
 QY 1261 ATCAGAGACTGACAGGAGCCCTTCAGTGTGATTAATTCAGAAACATCAGAGATAAC 1320  
 DB 1096 ATCAGAGACTGACAGGAGCCCTTCAGTGTGATTAATTCAGAAACATCAGAGATAAC 1155  
 QY 1321 ATTC 1324  
 DB 1156 ATTC 1159

RESULT 9  
 AAH07192  
 ID AAH07192 standard; cDNA; 796 BP.

XX AAH07192;

XX 26-JUN-2001 (first entry)

DE Human cDNA clone (5'-primer) SEQ ID NO:4027.

KX Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.

OS Homo sapiens.

XX  
 PN EP1074617-A2.  
 XX  
 PD 07-FEB-2001.  
 XX  
 PF 28-JUL-2000; 2000EP-0116126.  
 XX  
 PR 29-JUL-1999; 99JP-0248036.  
 XX  
 PR 27-AUG-1999; 99JP-0300253.  
 PR 11-JAN-2000; 2000JP-0118776.  
 PR 02-MAY-2000; 2000JP-0183767.  
 PR 09-JUN-2000; 2000JP-0241899.  
 XX  
 PA (HELI-) HELIX RES INST.  
 PI Ota T, Isegai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;  
 PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;  
 DR WPI; 2001-318749/34.  
 XX  
 PT Primer sets for synthesizing polynucleotides, particularly the 5602  
 PT full-length cDNAs defined in the specification, and for the detection  
 PT and/or diagnosis of the abnormality of the proteins encoded by the  
 PT full-length cDNAs -  
 XX  
 PS Claim 1; SEQ ID 4027; 2537pp + CD ROM; English.

The present invention describes primer sets for synthesizing 5602 full-length cDNAs defined in the specification. Where a primer set comprises: (a) an oligo-dT primer and an oligonucleotide complementary to the complementary strand of a polynucleotide which comprises one of the 5602 nucleotide sequences defined in the specification, where the oligonucleotide comprises at least 15 nucleotides; or (b) a combination of an oligonucleotide comprising a sequence complementary to the complementary strand of a polynucleotide which comprises a 5'-end sequence and an oligonucleotide comprising a sequence complementary to a polynucleotide which comprises a 3'-end sequence, where the oligonucleotide comprises at least 15 nucleotides and the combination of the 5'-end sequence/3'-end sequence is selected from those defined in the specification. The primer sets can be used in antisense therapy and in gene therapy. The primers are useful for synthesizing polynucleotides, particularly full-length cDNAs. The primers are also useful for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs. The primers allow obtaining of the full-length cDNAs easily without any specialised methods. AAH03166 to AAH13628 and AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632 represent oligonucleotides, all of which are used in the exemplification of the present invention.

XX  
 SQ Sequence 796 BP; 192 A; 204 C; 202 G; 195 T; 3 other;

Query Match 36.5%; Score 567; DB 22; Length 796;  
 Best Local Similarity 100.0%; Pred. No. 2.5e-273;  
 Matches 567; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTGATTGTAATCTGGTCTGTCAGAGACGACGAAAGAGATTGGTCAGAAAACTGC 60  
 DB 27 GTGATTGTAATCTGGTCTGTCAGAGACGACGAAAGAGATTGGTCAGAAAACTGC 86  
 QY 61 CCTGCCGACACAGACAGACGCGCCTAGTGGGAGAGGGTCTGCTGACTGACTTAATCG 120  
 DB 87 CCTGCCGACACAGACAGACGCGCCTAGTGGGAGAGGGTCTGCTGACTGACTTAATCG 146  
 QY 121 CTGTGCTGCTGGTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 180  
 DB 147 CTGTGCTGCTGGTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 206  
 QY 181 TAGATGAGTCCGACAGACAGTCCGCTTTGATGATTCCTGATCTGCAATTCCTCCGCTC 240  
 DB 207 TAGATGAGTCCGACAGACAGTCCGCTTTGATGATTCCTGATCTGCAATTCCTCCGCTC 266  
 QY 241 CTTCATGATTTGAAGGCT 300

```

Db      |||
267  CTTGATGATTGGAAGCTCTCTTCTTCTGAAAGACTTTCATCCCTCGTTGC 326
Qy      |||
301  TGAAGTTGGACAATGTTGATATACGTGTGAGAACCAAGCCACACATATCTGAATAC 360
Db      |||
327  TGAAGTTGGACAATGTTGATATACGTGTGAGAACCAAGCCACACATATCTGAATAC 386
Qy      |||
361  ACTTCTCTGACCAATGACCTGATGAGAAAGTATGATGAGAGGTGCTGCAAAAGAGGC 420
Db      |||
387  ACTTCTCTGACCAATGACCTGATGAGAAAGTATGATGAGAGGTGCTGCAAAAGAGGC 446
Qy      |||
421  AGACCTGATCTCTCTACCAATCCGCTATCTTCCGACCAATGAGGCAATACCTGAA 480
Db      |||
447  AGACCTGATCTCTCTACCAATCCGCTATCTTCCGACCAATGAGGCAATACCTGAA 506
Qy      |||
481  CACATGGAAGAGGCGCTGTGATCCGGCTCTTGAGAACAGAGTGGTATCTACTCTCC 540
Db      |||
507  CACATGGAAGAGGCGCTGTGATCCGGCTCTTGAGAACAGAGTGGTATCTACTCTCC 566
Qy      |||
541  TCATACAGCCTATGATGCTGGGCCCA 567
Db      |||
567  TCATACAGCCTATGATGCTGGGCCCA 593

```

## RESULT 10

AL23953  
ID AL23953 standard; cDNA; 462 BP.

XX AL23953;

XX 07-DEC-2001 (first entry)

DE Human breast cancer expressed polynucleotide 16410.

KM Human; breast cancer; cell marker; cytostatic; ss.

XX Homo sapiens.

XX W0200151628-A2.

XX 19-JUL-2001.

XX 10-JAN-2001; 2001WO-US00798.

XX 14-JAN-2000; 2000US-0176077.

XX 14-MAR-2000; 2000US-0189167.

XX 24-MAR-2000; 2000US-0192099.

XX 29-MAR-2000; 2000US-0193480.

XX 15-MAY-2000; 2000US-0205230.

XX 09-JUN-2000; 2000US-0211315.

XX 25-JUL-2000; 2000US-0220534.

XX (MILL-) MILENNIUM PREDICTIVE MEDICINE INC.

XX Lillie J, Xu Y, Wang Y, Steilmann K;

XX WPI; 2001-451856/48.

XX New peptide useful as a marker for the diagnosis of breast cancer

XX Claim 1; Page 3004; 3695pp; English.

XX The invention relates to human breast cancer expressed polynucleotides

XX (AL23953) and methods of assessing whether a patient is

XX afflicted with breast cancer by examining the correlation between the

XX expression of certain markers and the cancerous state of breast cells.

XX The polynucleotides and encoded polypeptides are potential markers for

XX detecting, diagnosing, monitoring, characterizing treating and

XX potentially preventing breast cancer. The polynucleotides and encoded

XX polypeptides are also useful for isolating compounds with cytostatic

XX activity.

XX Sequence 462 BP; 103 A; 126 C; 118 G; 115 T; 0 other;

Query Match 27.3%; Score 424; DB 22; Length 462;  
Best Local Similarity 100.0%; Pred. No. 1e-201;  
Matches 424; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy      |||
188  GTCCACAGACAGTCCGGTTGTAGATTCCTGATCTGCAATTCCTCCGCTTCATG 247
Db      |||
39  GTCCACAGACAGTCCGGTTGTAGATTCCTGATCTGCAATTCCTCCGCTTCATG 98
Qy      |||
248  GATTGAAGGCTCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 307
Db      |||
99  GATTGAAGGCTCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 158
Qy      |||
308  TGGACACATGTTGATATCTGTTGATATCTGTTGATATCTGTTGATATCTGTTGAT 367
Db      |||
159  TGGACACATGTTGATATCTGTTGATATCTGTTGATATCTGTTGATATCTGTTGAT 218
Qy      |||
368  CTGACCAATGACCTGATGAGAAAGTATGAGAGAGTGTGCAAAAGAGAGACCTC 427
Db      |||
219  CTGACCAATGACCTGATGAGAAAGTATGAGAGAGTGTGCAAAAGAGAGACCTC 278
Qy      |||
428  ATTCTCTCTACCAATCCGCTATCTTCTGACCAATGAAAGCCATTAACCTGACATG 487
Db      |||
279  ATTCTCTCTACCAATCCGCTATCTTCTGACCAATGAAAGCCATTAACCTGACATG 338
Qy      |||
488  AAGAGAGCCTGTGATCCGGCTCTGAGAAAGAGTGGTATCTACTCTCTCATACA 547
Db      |||
339  AAGAGAGCCTGTGATCCGGCTCTGAGAAAGAGTGGTATCTACTCTCTCATACA 398
Qy      |||
548  GCCATATGATGCTGCGCCCAAGGCGTCAACAAGTGTGCTTAAAGGCTTGAGCTTGT 607
Db      |||
399  GCCATATGATGCTGCGCCCAAGGCGTCAACAAGTGTGCTTAAAGGCTTGAGCTTGT 458
Qy      |||
608  AACT 611
Db      |||
459  AACT 462

```

## RESULT 11

AAK78763  
ID AAK78763 standard; DNA; 14969 BP.

XX AAK78763;

XX 07-NOV-2001 (first entry)

DE Human immune/haematopoietic antigen genomic sequence SEQ ID NO:33575.

KM Human; Immune; haematopoietic; Immune/haematopoietic antigen; cancer;

XX cytostatic; gene therapy; vaccine; metastasis; ds.

XX Homo sapiens.

XX W0200157182-A2.

XX 09-AUG-2001.

XX 17-JAN-2001; 2001WO-US01354.

XX 31-JAN-2000; 2000US-0179065.

XX 04-FEB-2000; 2000US-0180628.

XX 24-FEB-2000; 2000US-0184664.

XX 02-MAR-2000; 2000US-0186350.

XX 16-MAR-2000; 2000US-0189874.

XX 17-MAR-2000; 2000US-0190076.

XX 18-APR-2000; 2000US-0198123.

XX 19-MAY-2000; 2000US-0205515.

XX 07-JUN-2000; 2000US-0209467.

XX 28-JUN-2000; 2000US-0214886.

XX 30-JUN-2000; 2000US-0215135.

XX 07-JUL-2000; 2000US-0216647.

XX 07-JUL-2000; 2000US-0216880.

XX 11-JUL-2000; 2000US-0217487.

PR 11-JUL-2000; 2000US-0217496.  
 PR 14-JUL-2000; 2000US-0218290.  
 PR 26-JUL-2000; 2000US-0220964.  
 PR 14-AUG-2000; 2000US-0224518.  
 PR 14-AUG-2000; 2000US-0224519.  
 PR 14-AUG-2000; 2000US-0225213.  
 PR 14-AUG-2000; 2000US-0225214.  
 PR 14-AUG-2000; 2000US-0225266.  
 PR 14-AUG-2000; 2000US-0225267.  
 PR 14-AUG-2000; 2000US-0225268.  
 PR 14-AUG-2000; 2000US-0225270.  
 PR 14-AUG-2000; 2000US-0225447.  
 PR 14-AUG-2000; 2000US-0225757.  
 PR 14-AUG-2000; 2000US-0225758.  
 PR 14-AUG-2000; 2000US-0225759.  
 PR 18-AUG-2000; 2000US-0226279.  
 PR 22-AUG-2000; 2000US-0226681.  
 PR 22-AUG-2000; 2000US-0226686.  
 PR 22-AUG-2000; 2000US-0227182.  
 PR 23-AUG-2000; 2000US-0227009.  
 PR 30-AUG-2000; 2000US-0228924.  
 PR 01-SEP-2000; 2000US-0229287.  
 PR 01-SEP-2000; 2000US-0229343.  
 PR 01-SEP-2000; 2000US-0229344.  
 PR 01-SEP-2000; 2000US-0229345.  
 PR 05-SEP-2000; 2000US-0229509.  
 PR 05-SEP-2000; 2000US-0229513.  
 PR 06-SEP-2000; 2000US-0230437.  
 PR 06-SEP-2000; 2000US-0230438.  
 PR 08-SEP-2000; 2000US-0231242.  
 PR 08-SEP-2000; 2000US-0231243.  
 PR 08-SEP-2000; 2000US-0231244.  
 PR 08-SEP-2000; 2000US-0231413.  
 PR 08-SEP-2000; 2000US-0231414.  
 PR 08-SEP-2000; 2000US-0232080.  
 PR 08-SEP-2000; 2000US-0232081.  
 PR 12-SEP-2000; 2000US-0231968.  
 PR 14-SEP-2000; 2000US-0232397.  
 PR 14-SEP-2000; 2000US-0232398.  
 PR 14-SEP-2000; 2000US-0232399.  
 PR 14-SEP-2000; 2000US-0232400.  
 PR 14-SEP-2000; 2000US-0232401.  
 PR 14-SEP-2000; 2000US-0233063.  
 PR 14-SEP-2000; 2000US-0233064.  
 PR 14-SEP-2000; 2000US-0233065.  
 PR 21-SEP-2000; 2000US-0234223.  
 PR 21-SEP-2000; 2000US-0234274.  
 PR 25-SEP-2000; 2000US-0234997.  
 PR 25-SEP-2000; 2000US-0234998.  
 PR 26-SEP-2000; 2000US-0235484.  
 PR 27-SEP-2000; 2000US-0235634.  
 PR 27-SEP-2000; 2000US-0235636.  
 PR 29-SEP-2000; 2000US-0236327.  
 PR 29-SEP-2000; 2000US-0236367.  
 PR 29-SEP-2000; 2000US-0236368.  
 PR 29-SEP-2000; 2000US-0236369.  
 PR 29-SEP-2000; 2000US-0236370.  
 PR 02-OCT-2000; 2000US-0236802.  
 PR 02-OCT-2000; 2000US-0237037.  
 PR 02-OCT-2000; 2000US-0237038.  
 PR 02-OCT-2000; 2000US-0237039.  
 PR 02-OCT-2000; 2000US-0237040.  
 PR 13-OCT-2000; 2000US-0239935.  
 PR 13-OCT-2000; 2000US-0239937.  
 PR 20-OCT-2000; 2000US-0240960.  
 PR 20-OCT-2000; 2000US-0241221.  
 PR 20-OCT-2000; 2000US-0241785.  
 PR 20-OCT-2000; 2000US-0241786.  
 PR 20-OCT-2000; 2000US-0241787.  
 PR 20-OCT-2000; 2000US-0241808.  
 PR 20-OCT-2000; 2000US-0241809.  
 PR 20-OCT-2000; 2000US-0241826.

PR 01-NOV-2000; 2000US-0244617.  
 PR 08-NOV-2000; 2000US-0246474.  
 PR 08-NOV-2000; 2000US-0246475.  
 PR 08-NOV-2000; 2000US-0246476.  
 PR 08-NOV-2000; 2000US-0246477.  
 PR 08-NOV-2000; 2000US-0246478.  
 PR 08-NOV-2000; 2000US-0246523.  
 PR 08-NOV-2000; 2000US-0246524.  
 PR 08-NOV-2000; 2000US-0246525.  
 PR 08-NOV-2000; 2000US-0246526.  
 PR 08-NOV-2000; 2000US-0246527.  
 PR 08-NOV-2000; 2000US-0246528.  
 PR 08-NOV-2000; 2000US-0246532.  
 PR 08-NOV-2000; 2000US-0246609.  
 PR 08-NOV-2000; 2000US-0246610.  
 PR 08-NOV-2000; 2000US-0246611.  
 PR 08-NOV-2000; 2000US-0246613.  
 PR 17-NOV-2000; 2000US-0249207.  
 PR 17-NOV-2000; 2000US-0249208.  
 PR 17-NOV-2000; 2000US-0249209.  
 PR 17-NOV-2000; 2000US-0249210.  
 PR 17-NOV-2000; 2000US-0249211.  
 PR 17-NOV-2000; 2000US-0249212.  
 PR 17-NOV-2000; 2000US-0249213.  
 PR 17-NOV-2000; 2000US-0249214.  
 PR 17-NOV-2000; 2000US-0249215.  
 PR 17-NOV-2000; 2000US-0249216.  
 PR 17-NOV-2000; 2000US-0249217.  
 PR 17-NOV-2000; 2000US-0249218.  
 PR 17-NOV-2000; 2000US-0249244.  
 PR 17-NOV-2000; 2000US-0249245.  
 PR 17-NOV-2000; 2000US-0249264.  
 PR 17-NOV-2000; 2000US-0249265.  
 PR 17-NOV-2000; 2000US-0249297.  
 PR 17-NOV-2000; 2000US-0249299.  
 PR 17-NOV-2000; 2000US-0249300.  
 PR 01-DEC-2000; 2000US-0250160.  
 PR 01-DEC-2000; 2000US-0250391.  
 PR 05-DEC-2000; 2000US-0251030.  
 PR 05-DEC-2000; 2000US-0251988.  
 PR 05-DEC-2000; 2000US-0256719.  
 PR 06-DEC-2000; 2000US-0251479.  
 PR 08-DEC-2000; 2000US-0251856.  
 PR 08-DEC-2000; 2000US-0251868.  
 PR 08-DEC-2000; 2000US-0251869.  
 PR 08-DEC-2000; 2000US-0251889.  
 PR 08-DEC-2000; 2000US-0251990.  
 PR 11-DEC-2000; 2000US-0254097.  
 PR 05-JAN-2001; 2001US-0259678.  
 PA (HUMA-) HUMAN GENOME SCI INC.  
 XX  
 PI Rosen CA, Barash SC, Ruben SM.  
 XX  
 DR WPI; 2001-483426/52.  
 XX  
 PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,  
 PT useful for preventing, diagnosing and/or treating cancers and  
 PT metastasis -  
 XX  
 XX Disclosure; SEQ ID NO 33575; 3071pp + Sequence Listing; English.  
 XX  
 CC AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)  
 CC amino acid sequences given in AAM82170 to AAK91921. (I) have cytostatic  
 CC activity, and can be used in gene therapy and vaccine production. (I)  
 CC proteins and polynucleotides may be used in the prevention, diagnosis and  
 CC treatment of diseases associated with inappropriate (I) expression. For  
 CC example, they may be used to treat disorders associated with decreased  
 CC expression by rectifying mutations or deletions in a patient's genome  
 CC that affect the activity of (I) by expressing inactive proteins or to  
 CC supplement the patient's own production of (I). Additionally, (I)  
 CC polynucleotides may be used to produce the secreted (I), by inserting  
 CC the nucleic acids into a host cell and culturing the cell to express the



XX PN WO200151628-A2.  
XX PD 19-JUL-2001.  
XX PF 10-JAN-2001; 2001WO-US00798.  
XX PR 14-JAN-2000; 2000US-0176077.  
XX PR 14-MAR-2000; 2000US-0189167.  
XX PR 24-MAR-2000; 2000US-0192099.  
XX PR 29-MAR-2000; 2000US-0193480.  
XX PR 15-MAY-2000; 2000US-0205230.  
XX PR 09-JUN-2000; 2000US-0211315.  
XX PR 25-JUL-2000; 2000US-0220534.  
XX PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.  
XX PI Little J, Xu Y, Wang Y, Steinmann K;  
XX DR WPI; 2001-451856/48.  
XX PS New peptide useful as a marker for the diagnosis of breast cancer -  
XX PT Claim 1; Page 1361; 3695pp; English.  
XX PS The invention relates to human breast cancer expressed polynucleotides  
XX CC (AAL07544-AAL26789) and methods of assessing whether a patient is  
XX CC afflicted with breast cancer by examining the correlation between the  
XX CC expression of certain markers and the cancerous state of breast cells.  
XX CC The polynucleotides and encoded polypeptides are potential markers for  
XX CC detecting, diagnosing, monitoring, characterizing treating and  
XX CC potentially preventing breast cancer. The polynucleotides and encoded  
XX CC polypeptides are also useful for isolating compounds with cytostatic  
XX CC activity.  
XX SO Sequence 514 BP; 113 A; 141 C; 130 G; 126 T; 4 other;  
Query Match 21.2%; Score 329; DB 22; Length 514;  
Best Local Similarity 100.0%; Pred. No. 3.7e-154;  
Matches 329; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 188 GTCGCCAGCAGATCGGTTTGTAGATCCGATGCAATTCCTCCGCTTCATG 247  
DB 65 GTCCCGACGACGATCGGTTTGTAGATCCGATGCAATTCCTCCGCTTCATG 124  
QY 248 GATTGACGATCT 307  
DB 125 GATTGACGATCT 184  
QY 308 TGGGACATGTTGGATTACTGTGTGACCAAGCCACACATCTAATAATACCTTTC 367  
DB 185 TGGGACATGTTGGATTACTGTGTGACCAAGCCACACATCTAATAATACCTTTC 244  
QY 368 CTGACCAATGACCTGCTGAGAGAGATGAGAGAGAGAGAGAGAGAGAGAGAGAG 427  
DB 245 CTGACCAATGACCTGCTGAGAGAGATGAGAGAGAGAGAGAGAGAGAGAGAGAG 304  
QY 428 ATTCTCTCTACATCGGCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 487  
DB 305 ATTCTCTCTACATCGGCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 364  
QY 488 AAGGACGCTGCTGATCCGGGCTCTGGA 516  
DB 365 AAGGACGCTGCTGATCCGGGCTCTGGA 393  
RESULT 14  
AAK63571  
ID AAK63571 standard; cDNA; 463 BP.  
AC AAK63571;  
XX  
DT 06-NOV-2001 (first entry)

XX DE Human Immune/haematopoietic antigen encoding cDNA SEQ ID NO:8631.  
XX KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;  
XX KW cytostatic; gene therapy; vaccine; metastasis; ss.  
XX OS Homo sapiens.  
XX PN WO200157182-A2.  
XX PD 09-AUG-2001.  
XX PF 17-JAN-2001; 2001WO-US01354.  
XX PR 31-JAN-2000; 2000US-0179065.  
XX PR 04-FEB-2000; 2000US-0180628.  
XX PR 24-FEB-2000; 2000US-0184664.  
XX PR 02-MAR-2000; 2000US-0186350.  
XX PR 16-MAR-2000; 2000US-0189874.  
XX PR 17-MAR-2000; 2000US-0190076.  
XX PR 18-APR-2000; 2000US-0198123.  
XX PR 19-MAY-2000; 2000US-020515.  
XX PR 07-JUN-2000; 2000US-0209467.  
XX PR 28-JUN-2000; 2000US-0214886.  
XX PR 30-JUN-2000; 2000US-0215135.  
XX PR 07-JUL-2000; 2000US-0216647.  
XX PR 11-JUL-2000; 2000US-0217487.  
XX PR 11-JUL-2000; 2000US-0217496.  
XX PR 14-JUL-2000; 2000US-0218290.  
XX PR 26-JUL-2000; 2000US-0220963.  
XX PR 26-JUL-2000; 2000US-0220964.  
XX PR 14-AUG-2000; 2000US-0224518.  
XX PR 14-AUG-2000; 2000US-0224519.  
XX PR 14-AUG-2000; 2000US-0225213.  
XX PR 14-AUG-2000; 2000US-0225214.  
XX PR 14-AUG-2000; 2000US-0225266.  
XX PR 14-AUG-2000; 2000US-0225267.  
XX PR 14-AUG-2000; 2000US-0225268.  
XX PR 14-AUG-2000; 2000US-0225270.  
XX PR 14-AUG-2000; 2000US-022547.  
XX PR 14-AUG-2000; 2000US-0225757.  
XX PR 14-AUG-2000; 2000US-0225758.  
XX PR 14-AUG-2000; 2000US-0225759.  
XX PR 18-AUG-2000; 2000US-0226279.  
XX PR 22-AUG-2000; 2000US-0226681.  
XX PR 22-AUG-2000; 2000US-0226688.  
XX PR 22-AUG-2000; 2000US-0227182.  
XX PR 23-AUG-2000; 2000US-0227009.  
XX PR 30-AUG-2000; 2000US-0228924.  
XX PR 01-SEP-2000; 2000US-0229287.  
XX PR 01-SEP-2000; 2000US-0229343.  
XX PR 01-SEP-2000; 2000US-0229344.  
XX PR 01-SEP-2000; 2000US-0229345.  
XX PR 05-SEP-2000; 2000US-0229509.  
XX PR 05-SEP-2000; 2000US-0229513.  
XX PR 06-SEP-2000; 2000US-0230437.  
XX PR 06-SEP-2000; 2000US-0230438.  
XX PR 08-SEP-2000; 2000US-0231242.  
XX PR 08-SEP-2000; 2000US-0231243.  
XX PR 08-SEP-2000; 2000US-0231244.  
XX PR 08-SEP-2000; 2000US-0231413.  
XX PR 08-SEP-2000; 2000US-0231414.  
XX PR 08-SEP-2000; 2000US-0232080.  
XX PR 08-SEP-2000; 2000US-0232081.  
XX PR 12-SEP-2000; 2000US-0231968.  
XX PR 14-SEP-2000; 2000US-0232397.  
XX PR 14-SEP-2000; 2000US-0232398.  
XX PR 14-SEP-2000; 2000US-0232399.  
XX PR 14-SEP-2000; 2000US-0232400.  
XX PR 14-SEP-2000; 2000US-0232401.  
XX PR 14-SEP-2000; 2000US-0233063.  
XX PR 14-SEP-2000; 2000US-0233064.

PA	(HUMA-)	HUMAN GENOME SCI INC.
XX		
XX	Rosen CA,	Barash SC, Ruben SM;
XX		
DR	WPI:	2001-483426/52.
XX	P-PSDB:	AAM90790.
PT	Nucleic acids encoding human immune/hematopoietic antigen polypeptides,	
PT	useful for preventing, diagnosing and/or treating cancers and	
PT	metastasis -	
PS	Claim 1;	SEQ ID NO 8631; 3071bp + Sequence Listing; English.
XX		
CC	AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)	
CC	amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic	
CC	activity, and can be used in gene therapy and vaccine production. (I)	
CC	proteins, and polynucleotides may be used in the prevention, diagnosis and	
CC	treatment of diseases associated with inappropriate (I) expression. For	
CC	example, they may be used to treat disorders associated with decreased	
CC	expression by rectifying mutations or deletions in a patient's genome	
CC	that affect the activity of (I) by expressing inactive proteins or to	
CC	supplement the patients own production of (I). Additionally, (I)	
CC	polynucleotides may be used to produce the secreted (I), by inserting the	
CC	nucleic acids into a host cell and culturing the cell to express the	
CC	protein. (I) proteins and polynucleotides may be used to prevent,	
CC	diagnose and treat immune/hematopoietic-related diseases, especially	
CC	cancers and cancer metastasis of haematopoietic-derived cells. AAK64703	
CC	to AAK87694 represent human immune/hematopoietic antigen genomic	
CC	sequences from the present invention. AAK54942 to AAK54950 and AAM82169	
CC	represent sequences used in the exemplification of the present invention.	
XX		
SQ	Sequence 463 BP; 97 A; 103 C; 132 G; 126 T; 5 other;	
	Query Match	14.4%; Score 223; DB 22; Length 463;
	Best Local Similarity	99.6%; Pred. No. 4.5e-101;
	Matches	273; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	1	GTGATTGTTATCTTGTCGTCGACAGAGCAGACAGAGAGGAGATTGGGTCAGAAACTGC 60
DB	53	GTGATTGTTATCTTGTCGTCGTCGACAGAGCAGACAGAGGAGGAGATTGGGTCAGAAACTGC 112
QY	61	CCGTCGCGACACAGAGCAGAGGCACTAGTGGGACAGAGGGGCTCTGACTGACCTTAACG 120
DB	113	CCGTCGCGACACAGAGCAGAGGCACTAGTGGGACAGAGGGGCTCTGACTGACCTTAACG 172
QY	121	CTGTCGTCGCGATTTTTCACCTGTCCTGGAAGAGCCGTAAGTGGCACTGAAATGAGGCA 180
DB	173	CTGTCGTCGCGATTTTTCACCTGTCCTGGAAGAGCCGTAAGTGGCACTGAAATGAGGCA 232
QY	181	TAGATGAGTCCGCCACGACAGTCCGGTTGTAGATTCCCTGATCTGCATTTCTTCCGTT 240
DB	233	TAGATGAGTCCGCCACGACAGTCCGGTTGTAGATTCCCTGATCTGCATTTCTTCCGTT 292
QY	241	CTTCATGAGATTGGAAGGCTCTCCCTTTCTTCTT 274
DB	293	CTTCATGAGATTGGAAGGCTCTCCCTTTCTTCTT 326
	RESULT 15	
	ABA46423/C	
	ABA46423 standard; DNA; 465 BP.	
AC	ABA46423;	
XX		
DT	01-FEB-2002	(first entry)
XX		
DE	Human breast cell single exon nucleic acid probe #5118.	



